Rene Vollgraaff

Stay informed with Rene Vollgraaff’s coverage and analysis for Fortune.

  • A healthcare worker administers a SINOVAC Covid-19 vaccine on a minor during the Numolux/SINOVAC Paediatric Covid-19 Vaccine Clinical Trial at the Sefako Makgatho Health Sciences University in Pretoria, on September 10, 2021. – The primary objective of the study is to evaluate the efficacy of two doses of CoronaVac against confirmed symptomatic COVID-19 cases in children and adolescents aged 6 months to 17 years. Efficacy will also be evaluated against hospitalization and severe COVID-19 cases. The study worldwide will enroll 14 000 children and adolescents in various pediatric age group cohorts across 5 countries (South Africa, Chile, Philippines, Malaysia and Kenya). (Photo by Phill Magakoe / AFP) (Photo by PHILL MAGAKOE/AFP via Getty Images)Health

    South Africa could become COVID ‘mutation factory’ because of large HIV-infected population, scientists say

    By Rene Vollgraaff, Antony Sguazzin, and others